Results 101 to 110 of about 3,923 (195)
Treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) presents a growing clinical challenge. This study evaluated the in vitro efficacy of eravacycline and the potential synergistic activity of meropenem-vaborbactam in combination with either ...
Amira H. El-Ashry +4 more
doaj +1 more source
Background Bloodstream infection (BSI) is associated with poor outcomes especially when effective antimicrobial therapy and control of infection source are delayed.
Helio S. Sader +3 more
doaj +1 more source
In Vitro Activity of “Old” and “New” Antimicrobials against the Klebsiella pneumoniae Complex
The Klebsiella pneumoniae complex is a commonly isolated bacteria in human infections. These opportunistic pathogens pose a serious threat to public health due to their potential transmission to the human population.
Alicja Sękowska
doaj +1 more source
AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains ...
FATMA SENA TÜRKDOĞAN, Betigul Ongen
doaj +1 more source
Background Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia.
Helio S. Sader +4 more
doaj +1 more source
Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections [PDF]
Aims: Meropenem/vaborbactam combination is approved in adults by FDA and EMA for complicated urinary tract infections and by EMA also for other Gram-negative infections.
Tout, M +14 more
core +1 more source
Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) and Pseudomonas aeruginosa are leading causes of morbidity and mortality after lung transplantation (LuTx).
Andrea Lombardi +8 more
doaj +1 more source
Outline of Meropenem-Vaborbactam for the Treatment of Carbapenem-Resistant Enterobacteriaceae
Dr. Kush Nimron, Dr. Johncy Nathasha
openaire +1 more source
Antimicrobial activity of aztreonam/avibactam and molecular characterization of Enterobacterales not susceptible to ceftazidime/avibactam and/or meropenem/vaborbactam from US medical centres (2016-2024). [PDF]
Sader HS +5 more
europepmc +1 more source
In Vitro Activity of Imipenem-Funobactam Against Clinical Isolates of Gram-Negative Bacilli. [PDF]
Karlowsky JA +5 more
europepmc +1 more source

